Evaluation of efficacy of urinary uric acid excretion and urolithiasis related factor in urolithiasis patients with hyperuricemia by combination therapies of "Feburic tablets" and "Uralyt". - Evaluation of efficacy of urinary uric acid excretion and urolithiasis related factor in urolithiasis patients with hyperuricemia by combination therapies of "Feburic tablets" and "Uralyt".

Kanazawa Medical University0 个研究点目标入组 40 人开始时间: 2012年8月23日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) The patient who is developing gouty arthritis at the time of an eligibility judging, or has not passed two weeks since a gout arthritis disappearance day. 2) The patient who has not passed two weeks since the last medication day of the following combined use prohibition medicine at the time of an eligibility judging. Combined use prohibition drug of "Febric tablets". Mercaptopurine hydrate Azathioprine Combined use prohibition drug of "Uralyt". Hexamine mandelate 3) Serum creatinine level is more than 1.5 mg/dl. 4) Liver disease patients (either AST or ALT exceeds the twice of a standard value maximum). 5) Patients with severe cardiac disease, renal failure and other critical diseases. 6) Patients with drug allergy. 7) Patients who are considered to be inappropriate by the investigators.

发起方